

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: PAPADOPOULOS *et al.*
Title: Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties
Appl. No.: 10/009,852
§371 Date: December 6, 2001
Patent No.: 7,070,959
Grant Date: July 4, 2006
Assignee: Regeneron Pharmaceuticals, Inc.
Product: EYLEA® (aflibercept)

ELECTION IN ACCORDANCE WITH 37 C.F.R. § 1.785(b)

via EFS WEB

Mail Stop Hatch-Waxman PTE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Commissioner:

This communication is in response to the Notice of Final Determination and Requirement for Election ("Notice"), dated **March 17, 2016**, for the captioned patent. The Notice provided Applicant with an opportunity in accordance with 37 C.F.R. §1.785(b) to elect U.S. 7,070,959, U.S. 7,374,757, or U.S. 7,374,758 for patent term extension under 35 U.S.C. §156.

Applicant hereby elects **U.S.7,070,959** for patent term extension. Thus, Applicant respectfully requests a certificate of extension be issued for U.S. 7,070,959 for a period of 1,119 days, as indicated in the Notice, such that the expiration date of the extension is June 16, 2023. This election is timely because it is being filed by the April 17, 2016 due date set forth in the Notice.

No fee is believed to be due with this election. However, in the event a fee is required, the Commissioner is hereby authorized to charge any such fee to Deposit Account No. 18-0650.

Dated: April 5, 2016

Respectfully submitted,

By / Frank R. Cottingham /

Frank R. Cottingham
Attorney for Applicant
Reg. No. 50,437
Regeneron Pharmaceuticals, Inc.
Customer Number: 26693
777 Old Saw Mill River Road
Tarrytown, NY 10591
Direct Tel.: (914) 847-1116